Citi lowered the firm’s price target on DexCom (DXCM) to $85 from $105 and keeps a Buy rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: